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ABSTRACT The cloned DNA fragment of the cytochrome
P-450b/e gene containing the upstream region from position
-179 through part of the first exon is faithfully transcribed in
freeze-thawed rat liver nuclei. Phenobarbitone treatment of
the animal strikingly increases this transcription, and the
increase is blocked by cycloheximide (protein synthesis inhib-
itor) or CoCl2 (heme biosynthetic inhibitor) treatment of
animals. This picture correlates very well with the reported
cytochrome P-450b/e mRNA levels in vivo and run-on tran-
scription rates in vitro under these conditions. The upstream
region (from position -179) was assessed for protein binding
with nuclear extracts by nitrocellulose filter binding, gel re-
tardation, DNase I treatment ("footprinting"), and Western
blot analysis. Phenobarbitone treatment dramatically in-
creases protein binding to the upstream region, an increase
once again blocked by cycloheximide or CoCl2 treatments.
Addition of heme in vitro to heme-deficient nuclei and nuclear
extracts restores the induced levels of transcription and protein
binding to the upstream fragment, respectively. Thus, drug-
mediated synthesis and heme-modulated binding of a tran-
scription factor(s) appear involved in the transcriptional acti-
vation of the cytochrome P-450b/e genes, and an 85-kDa
protein may be a major factor in this regard.
Interaction of specific transcription factors with the cis-
acting elements in the 5'-flanking region of several eukaryotic
genes governs ligand-, tissue-, and cell-specific modulation of
gene expression. Thus, families of transcription factors in-
teracting with specific regulatory DNA sequences of eukary-
otic genes have been identified (1).
The cytochrome P-450 (P450) multigene family offers an
excellent system to study regulation of eukaryotic gene
expression, because this family responds to a variety of
environmental and developmental stimuli (2). Various re-
ports identify cis-acting elements, referred to as dioxin-
responsive elements, in different locations ranging from
positions -389 to -2263 of the mouse P-450 gene activated
by polycyclic hydrocarbons such as 2,3,7,8-tetrachlorodi-
benzo-p-dioxin and 3-methylcholanthrene (3-MC) (3, 4). Xe-
nobiotic responsive elements have been identified -1.0 ki-
lobase (kb) upstream of the RNA initiation site of the
hydrocarbon-responsive P-450c gene of rat liver and a xeno-
biotic responsive element-binding factor that is translocated
from the cytoplasm into the nucleus after dioxin treatment
has also been identified (5, 6). No information is available on
the function of the upstream regulatory elements of the
P-450b/e genes (phenobarbitone family).
In this laboratory, we have provided evidence that heme,
the prosthetic group of cytochrome P-450, is a positive
modulator of P-450 gene expression. The evidence is as
follows: (i) Inhibitors ofheme biosynthesis block induction of
P-450b/e and P-450c/d mRNAs by phenobarbitone and 3-
MC, respectively, in rats. (ii) Effects of these inhibitors can
be counteracted by exogenous hemin. (iii) Changes in the
mRNA levels in vivo correlate with their run-on transcription
rates with nuclei isolated from treated rat livers (7-10). In
addition, we have also shown that cycloheximide, a transla-
tion inhibitor, specifically blocks the transcriptional activa-
tion of P-450b/e and -c/d genes by phenobarbitone and
3-MC, respectively (11).
We reported the 5'-flanking sequence of the P-450b/e gene
to position -800, a sequence that contains several potential
regulatory sites (12). In the present study, we identify a drug-
and heme-modulated transcription factor(s) from rat liver.
Binding of this factor(s) to the 5'-flanking region of the
P-450b/e gene correlates well with the transcription status of
these genes.
MATERIALS AND METHODS
DNA Fragments and Probes. The plasmid pP450e4 was
used in in vitro transcription experiments. This plasmid
contains a 360-base pair (bp) fragment of the P-450e gene
(identical with the P450b gene except for four base substitu-
tions) cloned into the Sma I site of plasmid pUC19. The
fragment contains nucleotides from position -179 of the
upstream region and 181 nucleotides (nt) of the transcribed
region. The 360-bp fragment released with Sal I and EcoRI
(polylinker sites) from pP450e4 has a unique Nco I site at
position 29. The transcripts obtained in the in vitro transcrip-
tion experiments were analyzed by S1 nuclease protection
assay with a Nco I-EcoRI fragment (170 bp) that covered
some of the first exon labeled at the Nco I end and repre-
senting the coding strand (Fig. 1).
For nitrocellulose filter binding assays, the 360-bp fragment
released by EcoRI and Sal I and labeled at the 3' end with
[a-32P]dCTP was used. Gel-retardation and DNase I protec-
tion "footprinting" assays were performed with the Sal I-Nco
I fragment (223 bp), which covered the upstream region and 29
bp of the first exon. The DNA sequence, restriction sites, and
orientation of the probes appear in Fig. 1.
In Vitro Transcription and S1 Nuclease Protection Assays.
Cloned DNA, pP450e4, was added to freeze-thawed nuclei
and incubated under conditions described by Guertin et al.
(13). No radioactive precursor was added. The RNA tran-
scripts were isolated after DNase I and proteinase K treat-
ments and then hybridized to labeled Nco I-EcoRI fragment
(50,000 cpm), and S1 nuclease protection analysis was done
as described by Favaloro et al. (14). The protected fragment
was analyzed on urea-acrylamide (8%) gels and subjected to
autoradiography.
Nitrocellulose Filter Binding Assay. Nuclei were prepared
by citric acid buffer homogenization (15), the nuclear pellet
Abbreviations: 3-MC, 3-methylcholanthrene; P-450, cytochrome P-
450; nt, nucleotide(s).
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-179
GGCCTAAGCCCCAGTGCCCTTTTGI'CCTGT
TGAGGAGTGAIATAGCCAAAGCAGGAGGCGTGAACATCTGAAGTT-CATAA
CTGAGTGTAGGGGCAGATTCAGCATAAAAGATCCTGCTGGAGAGCATGCA
NcoI
CTGAAGTCTACCGI'GGTTACACCAGGACCATGGA(GCCCAGTATCT'T'GCT
CCTCCTTGCTCTCCTTGTGGGCTTCTTGTTACTCTTAGT'CAGGGGACACC
CAAAGTCCCGTGGCAACTTCCCACCAGGACCTCGTCCCCTTCCCCTCTTG
GGGAACCTCCTGCAGTTGGACAGAGGAGGCC
181
Ncol
FIG. 1. Nucleotide sequence of clone pP450e4. This plasmid
contains the 360-bp Hae III fragment of the P-450e gene (identical
with P-450b gene, except for four base substitutions) cloned into the
Sma I site ofpUC19. The upstream region (-179) from the RNA start
site is represented in boldface letters, and the exonic region is
represented in regular letters. The fragment was obtained by Hae III
digestion of the 1.0-kilobase (kb) fragment derived from clone
AP-450e5 (12). The 1.0-kb fragment contains the nt from position
-800 of the upstream region and 228 nt downstream. Polylinker sites
and the unique Nco I site used to generate the probes are indicated;
DNase I footprint region is boxed; consensus CCAAT binding site
and 13-bp imperfect palindrome are underlined.
was extracted, and the extract was dialyzed as described by
Strauss and Varshavsky (16). Filter binding assay was carried
out essentially as described by Diffley and Stillman (17).
Nuclear extracts were prepared by the addition ofNaCl to the
nuclear suspension (suspension buffer was 10 mM Tris HCl,
pH 7.5/50 mM NaCl/0.5 M sucrose/5 mM MgCl2/10 mM
dithiothreitol) to a final concentration of 0.45 M from a 4 M
stock solution. The suspension was left on ice for 30 min with
intermittent mixing; the suspension was then centrifuged,
and the supernatant was dialyzed against 10 mM Tris-HCl,
pH 7.5/1 mM EDTA/15% glycerol/10 mM 2-mercapto-
ethanol for 4 hr. The dialyzate was briefly centrifuged and
stored in aliquots at -80°C. The nuclear extract (3-5 ug of
protein) was then incubated with different concentrations 3f
competitor DNA (sonicated salmon sperm or calf thymus
DNA) in a volume of 20 ,ul in a buffer containing 25 mM
Hepes-NaOH, pH 7.5, 5 mM MgCl2, 2mM dithiothreitol, and
50mM NaCl at room temperature for 10 min. 32P-end-labeled
360-bp Sal I-EcoRI fragment (3000 cpm, -0.5 ng of DNA)
was then added, and incubation was continued for another 30
min. The mixture was then filtered through alkali-washed
nitrocellulose filters and washed three times-each time with
0.5 ml of wash buffer (25mM Tris HCl, pH 7.5/5mM MgCl2).
The filters were then dried and subjected to autoradiography.
Gel-Retardation Assay. The method was basically as de-
scribed by Ye and Samuels (18). For assay of the interaction
between nuclear extract and 32P-end-labeled pP45Oe4 frag-
ment, sonicated salmon sperm DNA was added at 400 ng.
After incubation, 2,ul of loading buffer [0.05% bromophenol
blue in 50% (vol/vol) glycerol] was added, and the samples
were analyzed on a 4% polyacrylamide gel (acrylamide/
bisacrylamide 30:1) in low-ionic-strength buffer (6.7 mM
Tris HCl, pH 7.5/3.3 mM sodium acetate/1 mM EDTA) at
40C for 3 hr (10 v/cm). The gel was then soaked in 10%
glycerol, dried, and subjected to autoradiography.
DNase I Footprinting. This procedure was carried out
essentially as described by Galas and Schmitz (19). DNA
sequencing was done by the method of Maxam and Gilbert
(20). The conditions were the same as for gel-retardation
analysis with the 32P-labeled Nco I-Sal I fragment, except
that the reaction was scaled up. DNase I was added to a final
concentration of 0.3 gg/ml and digested for 60 sec at room
temperature. The samples were extracted with phenol/
chloroform, and DNA fragments were precipitated with
ethanol. Fragments were analyzed on urea-polyacrylamide
(8%) sequencing gels.
Western Blotting. Nuclear extracts (100-150 ;Lg of protein)
were subjected to NaDodSO4/8% PAGE and transferred to
nitrocellulose by electrophoresis. Samples were mixed with
an equal volume of loading buffer (4% NaDodSO4/5 mM
TrisHCl, pH 6.8/200 mM 2-mercaptoethanol/20o glycerol/
0.05% bromophenol blue). The boiling step was omitted.
After electrophoresis, proteins were transferred to nitrocel-
lulose membrane by electrophoresis in a buffer containing 25
mM Trizma base and 190mM glycine for 16 hr at 100 mA. The
filters were first incubated in a blocking buffer (2% nonfat dry
milk/1% bovine serum albumin/10 mM Hepes-NaOH, pH
7.5/0.1 mM EDTA/60 mM NaCl/10 mM MgCl2/sonicated
salmon sperm DNA at 16 ,g/ml) for 2 hr at room tempera-
ture. The filters were then incubated in binding buffer (same
as blocking buffer except for 0.2% nonfat dry milk) contain-
ing nick-translated Sal I-EcoRI 360-bp pP450e4 DNA frag-
ment (106 Cerenkov cpm per ml) for 2 hr at room temperature.
The filters were then washed four times with wash buffer (10
mM Tris HCl, pH 7.5/0.1 mM EDTA/60 mM NaCl/0.05%
Nonidet P-40/0.2% nonfat dry milk) at room temperature,
dried, and subjected to autoradiography. The basic protocols
were as described by Miskiminis et al. (21).
RESULTS
In most protein coding genes, sequences up to 100 bp
upstream from the RNA start site regulate transcription,
although complex regulation is achieved by additional se-
quences that may be located even as far as 10,000 bp
upstream or downstream of the RNA start site (22). To
examine whether the near-upstream sequence regulates P-
450b/e gene expression, the plasmid pP450e4 containing base
pairs from position -179 upstream from the RNA start site
through a portion of the first exon (Fig. 1) was transcribed in
freeze-thawed nuclei isolated from rat livers under different
treatments. The transcripts were analyzed by S1 nuclease
mapping using labeled Nco I-EcoRI fragment derived from
the first exon. This treatment protected the 170- and 152-bp
fragments by transcripts derived from the added cloned DNA
and endogenous P-450b/e genes, respectively. (The strategy
is explained in Materials and Methods and in Fig. 2a). The
results (Fig. 2b) clearly indicate that the added cloned DNA
is transcribed in nuclei isolated from phenobarbitone-treated
rats several-fold higher than in control nuclei.
Nuclei isolated from heme-deficient rats (phenobarbitone
plus CoCl2-treated) show a striking decrease in transcription
of the added gene fragment; addition of hemin in vitro
counteracts the effects of CoCl2 treatment. Without added
DNA, the endogenous P-450b/e gene is significantly tran-
scribed in nuclei isolated from phenobarbitone-treated rats,
producing the expected 152-bp fragment. With added cloned
DNA, transcription of endogenous P-450b/e gene is sup-
pressed. Thus, freeze-thawed nuclei can faithfully transcribe
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FIG. 2. Transcription of pP450e4 DNA with frozen-thawed rat
liver nuclei in vitro. (a) The probe used for S1 nuclease protection
analysis of the in vitro transcripts and the generation of different-
sized protected fragments derived from endogenous transcripts and
protected fragments derived from added pP450e4 plasmid are indi-
cated. Thick line (18 bp) indicates the polylinker region. (b) Auto-
radiographic analysis of S1 nuclease-protected fragments generated
by the RNA transcripts. Lanes: 1, no RNA; 2, control nuclei and
pP450e4 DNA; 3, phenobarbitone nuclei and pP450e4 DNA; 4,
phenobarbitone plus CoC12 nuclei and pP450e4 DNA; 5, phenobar-
bitone plus CoC12 nuclei and pP450e4 DNA plus hemin (10-5 M)
added in vitro; 6, phenobarbitone nuclei with no added DNA; 7,
phenobarbitone nuclei and pUC19 DNA. Animals were sacrificed 4
hr after drug and other treatments.
added P-450b/e gene fragment, and the result correlates well
with changes in P-450b/e mRNA levels in vivo and run-on
transcription rates in vitro reported earlier (8, 10). Because
transcription of the added gene fragment should involve fresh
initiation, the upstream sequence (from position -179) prob-
ably has sites for interaction with protein factors modulating
transcription of P450b/e genes.
Therefore, nitrocellulose filter binding was assayed with
nuclear extracts and labeled Sal I-EcoRI 360-bp fragment
containing the upstream sequence and part of the first exon.
The results (Fig. 3) indicate that when binding is done with
400 ng of unlabeled competitor DNA and 32P-labeled 360-bp
fragment, the nuclear extracts prepared from phenobarbi-
tone-treated rat liver (phenobarbitone-nuclear extract) bind
significantly, whereas the control extract shows little bind-
ing. Treatment of animals with cycloheximide or CoC12
FIG. 3. Nitrocellulose filter binding assay of the interaction
between the nuclear extracts and the labeled pP450e4 fragment.
Rows: 1, control extract; 2, phenobarbitone extract; 3, phenobar-
bitone plus cycloheximide extract; 4, phenobarbitone plus CoC12
extract. Columns: A, no competitor DNA; B, 200 ng; C, 300 ng; D,
400 ng of competitor DNA.
blocks the significant binding seen with the phenobarbitone-
nuclear extracts. These results are significant because they
correlate exactly with the pattern ofP-450b/e gene transcrip-
tion obtained under the different treatment conditions. The
results obtained with the nitrocellulose filter binding assay
have been rather variable in quantitative terms, although the
pattern obtained has been highly reproducible.
Confirmation of these results was obtained with gel-
retardation experiments. For this purpose, the 360-bp Sal I-
EcoRI fragment or the Nco I-cut fragments Sal I-Nco I and
Nco I-EcoRI were used. Fig. 4 a and b shows that the major
complex seen with phenobarbitone-nuclear extract is barely
visible in control nuclear extract. The inhibitory effects of
CoC12 and cycloheximide treatments are also clearly seen.
Interestingly addition of hemin in vitro to heme-deficient
nuclear extracts restores complex formation (Fig. 4b). In
separate experiments, we also found that nuclear extracts
prepared from phenobarbitone plus CoC12-treated animals
given hemin in vivo also significantly restore (=60%) complex
formation (data not shown). Fig. Sa indicates that protein
binds mostly with the Sal I-Nco I fragment (covering from
position -179 of the upstream region to position 29 of the
exon) and much less with the Nco I-EcoRI fragment (cov-
ering some of the first exon). This result shows binding to
occur essentially with the upstream region. Fig. Sb indicates
specificity of binding; binding is abolished with excess un-
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FIG. 4. Gel-retardation assay of the interaction between the nu-
clear extract and 32P-end-labeled pP450e4 fragment. (a) Lanes: 1,
control extract; 2, phenobarbitone extract; 3, phenobarbitone plus
cycloheximide extract; 4, phenobarbitone plus CoC12 extract; Sal I-
EcoRI (360 bp) fragment was used. (b) Lanes: 1, control extract; 2,
phenobarbitone extract (1-hr treatment); 3, phenobarbitone and CoC12
extract (1-hr treatment); 4, phenobarbitone and CoC12 extract (3-hr
treatment); 5, phenobarbitone and CoC12 extract (5-hr treatment); 6,
phenobarbitone and CoC12 extract (5-hr treatment) plus hemin (10-5
M) in vitro; 7, phenobarbitone and CoC12 extract (5-hr treatment) plus
hemin (10-6 M) in vitro. Sal I-Nco I (223-bp) fragment was used.
Incubation conditions were as described for Fig. 3.
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FIG. 5. Gel-retardation assay. (aI) Sal I-Nco 1 (223 bp) upstream fragment was used as a probe. Lanes: 1, control extract; 2, phenobarbitone
extract; 3, phenobarbitone and CoC12 extract; 4, phenobarbitone and cycloheximide extract. (all) Nco I-EcoRI (170 bp) exon fragment was used
as probe. Lanes: 1, free DNA; 2, control extract; 3, phenobarbitone extract; 4, phenobarbitone and CoCl2 extract; 5, phenobarbitone and
cycloheximide extract. (b) Labeled Sal I-Nco I upstream fragment was used with phenobarbitone extract and different combinations of
competitor DNA. Lanes: 1, 300 ng of salmon sperm DNA plus 100 ng of pUC19 DNA; 2, 300 ng of salmon sperm DNA plus 100 ng of M13
DNA; 3, 300 ng of salmon sperm DNA plus 100 ng of unlabeled Sal I-Nco I fragment; 4, 400 ng of salmon sperm DNA; 5, free labeled DNA.
labeled homologous fragment but not with excess pUC19 or
M13 DNA fragments.
Fig. 6 shows the DNase I footprint obtained with the
phenobarbitone-nuclear extract and the Sal I-Nco I frag-
ment. A 32-bp protected region between nt -56 and -88 can
be discerned.
Finally, Western blot analysis of the nuclear extracts was
done, and the blots were probed with nick-translated pP450e4
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FIG. 6. DNase I footprinting analysis. Lanes: 1, G reaction; 2, C
reaction; 3, without nuclear extract; 4, phenobarbitone-nuclear ex-
tract (50 Ag of protein); and 5, phenobarbitone-nuclear extract (75 ,g
of protein). Protected sequence is indicated.
DNA. The results (Fig. 7) show a striking increase in the band
corresponding to Mr 85,000 in phenobarbitone treatment,
which is abolished with CoCl2 or cycloheximide treatments.
A few other bands also increase to a minor degree after
phenobarbitone treatment. The intense bands seen at the
bottom of the gel are generated by histones.
DISCUSSION
This study has led to several important observations. The
cloned P-450b/e gene fragment containing base pairs from
position -179 of the upstream region and some of the first
exon is faithfully transcribed in freeze-thawed nuclei, exactly
reflecting the drug-mediated induction, as well as the block
seen under heme-deficient conditions in mRNA levels in vivo
and run-on transcription experiments in vitro.
1 2 3 4
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FIG. 7. Western blot analysis. Lanes: 1, control extract; 2,
phenobarbitone extract; 3, phenobarbitone plus CoCl2 extract; and
4, phenobarbitone plus cycloheximide extract.
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Nuclear protein-binding experiments revealed that binding
of a protein factor(s) to the upstream region significantly
increases after phenobarbitone treatment, and this increase is
blocked by heme deficiency or cycloheximide treatment.
This result has been confirmed with nitrocellulose filter
binding, gel retardation, and Western blot analysis. The
striking correlation between patterns of binding and tran-
scription under different treatment conditions indicates that
the drug may induce synthesis ofa transcription factor, which
itself is hemoprotein in nature; binding of this factor to the
upstream region would activate transcription. Cyclohexi-
mide would then block P-450b/e gene transcription because
it blocks synthesis of the transcription factor. CoCl2 can
block transcription because CoC12 inhibits heme synthesis
and the hemoprotein transcription factor requires heme for
binding. This suggestion is supported by the observation that
binding of such extracts to the DNA fragment is restored by
adding hemin in vitro. Other models can be based on heme
regulation of the phosphorylation status of the transcription
factor and modulation of association/dissociation with an
inhibitor. Further studies are needed to distinguish between
these various hypotheses.
This report provides direct evidence for the involvement of
heme in modulating interaction of the promoter region with
a transcription factor(s); heme has earlier been reported to
regulate the transcription of iso-1-cytochrome c gene in yeast
(23). A heme-activated protein (HAP) gene product) was
suggested to pick up heme in the cytosol and bind to the
upstream activation sequence of the iso-1-cytochrome c
gene. The in vitro addition of heme was shown to stimulate
HAP) binding to the upstream activation sequence. The
similarity of these observations to the present study is
striking.
Recently, HAP gene products (HAP2 and HAP3 proteins)
along with a host of other eukaryotic transcription factors
have been categorized as CCAAT binding proteins. These
proteins show similarities in their preferences for different
forms of their DNA-binding sites, making identical contacts
with the bound DNA. Such factors thus show specificity,
while at the same time performing diverse functions, such as
activation of transcription and replication-perhaps through
microheterogeneity in their structures and heteromer forma-
tion (24, 25). An analysis of the 32-bp protected fragment
obtained in our study does indicate the presence of the
NGCCAAN sequence, the consensus sequence for nuclear
factor I and other factors (24), followed by a 13-bp imperfect
palindrome (Fig. 1).
At this stage, whether the transcription factor(s) identified
in our study can be a drug receptor as well is not clear.
Although the hydrocarbons act through a receptor (2), efforts
to identify a receptor protein for phenobarbitone have not
been very successful (26). Also the question remains whether
the same or a similar transcription factor is induced by 3-MC
because we have shown that both cycloheximide and CoC12
block 3-MC-mediated activation of P-450c/d genes as well
(11). Further studies are needed to resolve many of these
issues. Clearly, however, drug-mediated synthesis and heme-
modulated binding of specific transcription factor(s) are
involved in transcriptional activation of the P-450b/e gene
system, and an 85-kDa protein may play a major role in this
activity.
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